Adicet Bio

Adicet Bio announced the first patient dosed in a Phase 1 trial of ADI-270 for metastatic/advanced clear cell renal cell carcinoma (ccRCC), with preliminary data expected in H1 2025. ADI-270 is an allogeneic gamma delta CAR T cell therapy targeting CD70-positive cancers, designed to improve clinical responses in RCC patients.

Adicet Bio opens enrollment for Phase 1 trial of ADI-270, an allogeneic gamma delta CAR T cell therapy targeting metastatic/advanced clear cell renal cell carcinoma (ccRCC), with preliminary data expected in H1 2025.

Adicet Bio, Inc. announced an oral presentation at ASGCT’s 2024 conference on ADI-270, an allogeneic anti-CD70 CAR γδ T cell therapy for cancer, presented by Shon Green, Ph.D. on October 17, 2024.